--- title: "60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 162.09 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/286563085.md" datetime: "2026-05-15T12:13:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286563085.md) - [en](https://longbridge.com/en/news/286563085.md) - [zh-HK](https://longbridge.com/zh-HK/news/286563085.md) --- # 60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 162.09 K Revenue: As of FY2026 Q1, the actual value is USD 162.09 K. EPS: As of FY2026 Q1, the actual value is USD -1.28. EBIT: As of FY2026 Q1, the actual value is USD -2.105 M. 60 Degrees Pharmaceuticals, Inc. operates as a single identifiable segment focused on developing and marketing new medicines for infectious diseases . #### Segment Revenue Product revenues, net of discounts and rebates, for the three months ended March 31, 2026, were $162,092, representing a -0.89% decrease from $163,552 in the prior-year period, primarily due to returns associated with expiring product lots . In Q1 2026, the U.S. pharmaceutical distributor accounted for 90% of total net product sales of Arakoda, while Kodatef sales to the Australian distributor accounted for 10% . Sales volume of Arakoda (16-ct box equivalents) decreased by 19% from 1,579 boxes in Q1 2025 to 1,276 boxes in Q1 2026 . Kodatef sales to Biocelect in Australia were $15,470 in Q1 2026, up from $12,066 in Q1 2025, though sales volume decreased by 8% to 354 boxes . Arakoda sales volume in Europe, through Scandinavian Biopharma, increased by 5% to 77 boxes in Q1 2026 . Research revenues were $0 for the three months ended March 31, 2026, a -100.00% decrease from $92,731 in the prior-year period, as the USAMMDA contract was fully utilized by the end of 2025 . #### Operational Metrics Cost of revenues increased by 16.98% to $85,715 for the three months ended March 31, 2026, from $73,272 in the prior-year period, mainly due to higher quarterly storage costs . Gross profit decreased by -15.40% to $76,377 in Q1 2026 from $90,280 in Q1 2025, with gross margin declining from 55.20% to 47.12% . Total operating expenses increased by 3.70% to $2,171,338 in Q1 2026 from $2,093,949 in Q1 2025 . Research and development costs decreased by -24.10% to $281,464, primarily due to the absence of packaging validation costs incurred in the prior year . General and administrative expenses rose by 9.68% to $1,889,874, driven by higher sales, advertising, and promotion expenses, and increased audit, legal, and professional fees . Loss from operations for the three months ended March 31, 2026, was - $2,094,961, compared to - $1,910,938 in the same period of 2025 . Net loss attributable to 60 Degrees Pharmaceuticals, Inc. was - $2,089,214 for the three months ended March 31, 2026, compared to - $1,876,549 in the prior-year period . #### Cash Flow Net cash used in operating activities increased by 71.63% to - $2,741,559 for the three months ended March 31, 2026, from - $1,597,366 in the prior-year period, driven by higher general and administrative expenses and increased vendor prepayments for API production . Net cash provided by investing activities was $1,193,560, a decrease from $1,702,518 in the prior-year period, mainly due to proceeds from maturities of short-term investments . Net cash provided by financing activities significantly increased by 98.58% to $3,369,752, primarily due to higher net proceeds from At-the-Market (ATM) offerings . #### Outlook and Strategy 60 Degrees Pharmaceuticals, Inc. estimates it will have sufficient funds to operate through mid-September 2026, assuming no additional capital raises, based on current internal projections and recent proceeds from public offerings . However, the company does not have sufficient cash and cash equivalents to fund its operating plan for the next 12 months, raising substantial doubt about its ability to continue as a going concern . Management plans to fund operations through third-party and related-party debt/advances, private placement of restricted securities, and subsequent stock offerings to achieve profitability or a business combination . ### Related Stocks - [SXTPW.US](https://longbridge.com/en/quote/SXTPW.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [FRONTERA ANNOUNCES FIRST QUARTER 2026 RESULTS | FECCF Stock News](https://longbridge.com/en/news/286507909.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Elkem updates financial calendar for 2026 reporting schedule](https://longbridge.com/en/news/286917298.md)